Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease.

Viktoria BergqvistJohanna HolmgrenDaniel KlintmanJan Marsal

Published in: Alimentary pharmacology & therapeutics (2022)

The switch from intravenous to subcutaneous vedolizumab could be done with preserved therapeutic effectiveness, safety, high patient satisfaction and low discontinuation rate, at a reduced cost.

Keyphrases

patients with inflammatory bowel disease
patient satisfaction
high dose
randomized controlled trial
systematic review
electronic health record
ulcerative colitis
big data
low dose
machine learning
data analysis